How can gene therapy expression be precisely controlled on-demand for the delicate excitatory/inhibitory balance in epilepsy?

The abstract identifies expression controllability as a major challenge, noting that reconfiguring excitatory and inhibitory properties in epilepsy is a delicate process requiring on-demand control. Current gene therapy lacks precise temporal and spatial expression control mechanisms.

Gap type: open_question Source paper: Recent advances and current status of gene therapy for epilepsy. (2024, World journal of pediatrics : WJP, PMID:39395088)

Resolved when an on-demand epilepsy gene-therapy control system demonstrates reversible, cell-type-specific tuning of excitatory/inhibitory balance in vivo. Required evidence: inducible or activity-responsive promoter/vector design, quantitative expression kinetics, seizure-frequency reduction, electrophysiology showing restored E/I balance, off-state leak measurement, and safety after repeated induction cycles. Closure requires demonstrating clinically relevant temporal control without persistent overexpression or network destabilization.